Glenmark Pharmaceuticals Limited — Updates, 29-05-2026: General Updates

Glenmark Pharma will transfer its Nebulizer brands/IP portfolio to its wholly-owned subsidiary for Rs. 223 Cr cash. This strategic move aims to create a focused entity, enhance operational agility, and capitalize on the robust growth of its respiratory innovation business.